Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7649942 | 0.98 | HRH3 (0.52) | HRH3ALOX15CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL16312397 | 0.93 | HRH3 (0.61) | HRH3ALOX15CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL8471267 | 0.91 | HRH3 (0.56) | HRH3ALOX15CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL27699518 | 0.87 | — | — | |
| SCHEMBL9434876 | 0.87 | ALOX15 (0.50) | HRH3ALOX15SMN1; SMN2SLC6A4HRH1 | |
| SCHEMBL20333472 | 0.86 | HRH3 (0.56) | HRH3CYP1A2MAPK1SMN1; SMN2SIGMAR1 | |
| SCHEMBL19040055 | 0.86 | HRH3 (0.58) | HRH3SIGMAR1 | |
| SCHEMBL19040056 | 0.86 | HRH3 (0.58) | HRH3SIGMAR1 | |
| SCHEMBL24891404 | 0.85 | HRH3 (0.48) | HRH3SIGMAR1SLC6A4 | |
| SCHEMBL24891390 | 0.85 | HRH3 (0.48) | HRH3SIGMAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2022093817-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3267794-B1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3134409-B1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS | UNIV MONTREAL (CA) | 2020-02-12 | — | — | EP | disclosed |
| EP-3194602-B1 | COMPOUNDS AND METHODS FOR ENHANCING VIRAL GENE TRANSFER TO HUMAN HEMATOPOIETIC CELLS | UNIV MONTREAL (CA) | 2019-11-06 | — | — | EP | disclosed |
| EP-3336084-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-9708305-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases | UNIVERSITé LAVAL (CA) | 2017-07-18 | — | — | US | disclosed |
| US-9708305-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases | UNIVERSITé LAVAL (CA) | 2017-07-18 | — | — | US | disclosed |
| US-20170037047-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS | UNIVERSITE DE MONTREAL (CA) | 2017-02-09 | — | — | US | disclosed |
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | UNIVERSITé LAVAL (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | UNIVERSITé LAVAL (CA) | 2016-07-14 | — | — | US | disclosed |
| WO-2016041080-A1 | COMPOUNDS AND METHODS FOR ENHANCING VIRAL GENE TRANSFER TO HUMAN HEMATOPOIETIC CELLS | Université de Montréal (CA) | 2016-03-24 | — | — | WO | disclosed |
| WO-2015024111-A1 | COMPOUNDS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | UNIVERSITE LAVAL (CA) | 2015-02-26 | — | — | WO | disclosed |
| US-8044213-B2 | Thiazolyl-benzimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CAI JIANPING | 2010-06-24 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| US-6479672-B1 | Diastereoselective preparation of Michael adducts | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037047-A1 | COMPOUNDS AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS AND/OR HEMATOPOIETIC PROGENITOR CELLS | HPGDS, HCLS1, THPO | HRH3 369/4885ALOX15 831/4885CYP1A2 730/4885 |
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | STS, SHBG, CYP19A1 | HRH3 238/4885ALOX15 1440/4885CYP1A2 193/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | HRH3 3657/4885ALOX15 513/4885CYP1A2 3293/4885 |
| US-20100160308-A1 | Thiazolyl-Benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | HRH3 1953/4885ALOX15 3836/4885CYP1A2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.